Rate of select adverse events with select doublet and triplet regimens
| Adverse event . | AO (ELEVATE TN)a . | VO (CLL14)b . | IV (Captivate FD cohort)c . | IV (GLOW)d . | IVO (GAIA/CLL13)e . | AVO (phase 2)f . | ZVO (BOVen)g . |
|---|---|---|---|---|---|---|---|
| Grade 3+ neutropenia | 30.9% | 52.8% | 33% | 34.9% | 48% | 43% | 18% |
| Grade 3+ thrombocytopenia | NR | 14.2% | 13% | 5.7% | 16% | 27% | 8% |
| Hypertension | 7.9% | 3.3% (G3+) | 16% | 7.5% (G3+) | 12.5% | 11% | 13% |
| Atrial fibrillation | 3.9% | 2.4% (G3+) | 4% | 6.6% (G3+) | 7.8% | 3% | 2.5% |
| Grade 3+ bleeding or major bleeding | 2.8% | NR | 2% | NR | NR | 0 | 3% |
| Infection | 75.3% | NR | 67% | NR | NR | 14% | NR |
| Grade 3+ infection | 23.6% | NR | 8% | 17% | NR | 3% | NR |
| Secondary malignancies total/total minus nonmelanoma skin cancers | 15.7%/8.4% | 22.2%/13.2% | NR | 0.9% | 17% | NR | NR |
| Discontinuation of therapy for AE | 13% | 16% | 1% | 10.4% | NR | NR | NR |
| Adverse event . | AO (ELEVATE TN)a . | VO (CLL14)b . | IV (Captivate FD cohort)c . | IV (GLOW)d . | IVO (GAIA/CLL13)e . | AVO (phase 2)f . | ZVO (BOVen)g . |
|---|---|---|---|---|---|---|---|
| Grade 3+ neutropenia | 30.9% | 52.8% | 33% | 34.9% | 48% | 43% | 18% |
| Grade 3+ thrombocytopenia | NR | 14.2% | 13% | 5.7% | 16% | 27% | 8% |
| Hypertension | 7.9% | 3.3% (G3+) | 16% | 7.5% (G3+) | 12.5% | 11% | 13% |
| Atrial fibrillation | 3.9% | 2.4% (G3+) | 4% | 6.6% (G3+) | 7.8% | 3% | 2.5% |
| Grade 3+ bleeding or major bleeding | 2.8% | NR | 2% | NR | NR | 0 | 3% |
| Infection | 75.3% | NR | 67% | NR | NR | 14% | NR |
| Grade 3+ infection | 23.6% | NR | 8% | 17% | NR | 3% | NR |
| Secondary malignancies total/total minus nonmelanoma skin cancers | 15.7%/8.4% | 22.2%/13.2% | NR | 0.9% | 17% | NR | NR |
| Discontinuation of therapy for AE | 13% | 16% | 1% | 10.4% | NR | NR | NR |
aMedian follow-up 46.9 months; bMedian follow-up 66.7 months; cMedian follow-up 27.9 months; dMedian follow-up 27.7 months; eMedian follow-up 50.7 months; fMedian follow-up 27.6 months; gMedian follow-up 25.8 months.
NR, not reported.